Merck is not dumb. They're not in the business of losing money.

If the generic doesn't get out there then the pharmaceutical company (with the patent) obviously benefits.

The more the two companies discussed co-heads, the more difficult it became.

These are the two biggest companies in the cholesterol segment, companies with combined annual revenues of $12 billion, and (the guidelines) could add a couple of billion to each company over five years.

This was an extremely difficult decision for Siemens to make. However, the business has been losing money for eight years despite our attempts to improve operational efficiencies and introduce new products.

You put it all together and what it tells me is they're losing more business than they're selling. And that's a worrisome sign.